$6.92
5.72% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Stock price

$7.34
+1.42 23.88% 1M
-1.97 21.16% 6M
-1.20 14.05% YTD
-1.14 13.44% 1Y
+2.12 40.61% 3Y
+2.58 54.20% 5Y
-33.55 82.05% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.80 12.23%
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Key metrics

Market capitalization $1.17b
Enterprise Value $850.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.35
P/S ratio (TTM) P/S ratio 18.32
P/B ratio (TTM) P/B ratio 3.67
Revenue growth (TTM) Revenue growth 9.03%
Revenue (TTM) Revenue $63.72m
EBIT (operating result TTM) EBIT $-171.78m
Free Cash Flow (TTM) Free Cash Flow $-135.97m
Cash position $392.10m
EPS (TTM) EPS $-1.26
P/E forward negative
P/S forward 16.46
EV/Sales forward 12.00
Short interest 8.10%
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Ocular Therapeutix Inc forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
100%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
64 64
9% 9%
100%
- Direct Costs 5.63 5.63
7% 7%
9%
58 58
9% 9%
91%
- Selling and Administrative Expenses 98 98
38% 38%
155%
- Research and Development Expense 128 128
109% 109%
200%
-168 -168
112% 112%
-264%
- Depreciation and Amortization 3.79 3.79
27% 27%
6%
EBIT (Operating Income) EBIT -172 -172
109% 109%
-270%
Net Profit -194 -194
140% 140%
-304%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
3 days ago
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
Positive
The Motley Fool
20 days ago
The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.
Positive
Seeking Alpha
28 days ago
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 274
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today